NASDAQ:VTVT - vTv Therapeutics Stock Price, Price Target & More

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

vTv Therapeutics Inc (NASDAQ:VTVT) issued its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.04. The biotechnology company earned $2.06 million during the quarter, compared to analyst estimates of $3.14 million. View vTv Therapeutics' Earnings History.

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for vTv Therapeutics.

8 Wall Street analysts have issued 12 month price objectives for vTv Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they anticipate vTv Therapeutics' share price to reach $14.7143 in the next twelve months. This suggests a possible upside of 921.8% from the stock's current price. View Analyst Ratings for vTv Therapeutics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to vTv Therapeutics include ContraFect (CFRX), Tocagen (TOCA), Menlo Therapeutics (MNLO), Neos Therapeutics (NEOS), Syndax Pharmaceuticals (SNDX), VERONA PHARMA P/S (VRNA), VBI Vaccines (VBIV), Nature's Sunshine Products Common Stock (NATR), BioXcel Therapeutics (BTAI), NewLink Genetics (NLNK), Innovate Biopharmaceuticals (INNT), Protagonist Therapeutics (PTGX), Tetraphase Pharmaceuticals (TTPH), Newron Pharmaceuticals (NWPHF) and Spero Therapeutics (SPRO).

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

News coverage about VTVT stock has been trending somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. vTv Therapeutics earned a coverage optimism score of 0.12 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.08 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

vTv Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include MACANDREWS & FORBES INC. (79.80%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of VTVT stock can currently be purchased for approximately $1.44.

vTv Therapeutics has a market capitalization of $47.59 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe.

vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PARKWAY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]